STAAR Surgical Company

Shares of several medical device companies fell after Intuitive Surgical warned that changes to some insurance plans could slow U.S. procedure growth, sparking fears of a sector-wide slowdown. STAAR Surgical dropped 10.1%, Globus Medical fell 4.4%, Integer Holdings declined 4.1%, and Enovis lost 5.1%. The warning suggests that shifting insurance coverage could dampen the number of medical procedures performed in the United States, creating headwinds for the entire industry reliant on steady procedure volumes.

STAAR Surgical shares fell about 10% on Friday, potentially the worst one-day drop since February 2025, even after the company reported preliminary second-quarter net sales exceeding $90 million, above the $89.4 million analyst consensus and more than double the prior-year period. Jefferies analyst Young Li noted management did not provide second-half guidance and continued to express caution, saying investors want guidance before becoming more constructive. Needham’s David Saxon wrote that the preannouncement lowers the bar for the second half but adds ambiguity, while BTIG’s Ryan Zimmerman cited similar concerns, pointing to seasonality in the Chinese market as a key overhang and the lack of full-year revenue guidance.

Stock futures edged lower early Friday as a major correction in the semiconductor space overshadowed a supportive domestic inflation backdrop. Netflix shares plunged 10% after the streaming giant reported mixed second-quarter results, with revenue narrowly missing expectations and full-year revenue guidance of 51.0 billion to 51.4 billion dollars coming in below the 51.4 billion dollar consensus. SpaceX fell 5% after an automatic launch abort of its upgraded Starship V3 rocket extended a five-day losing streak that pushed shares further below their 135 dollar IPO price. STAAR Surgical tumbled 12% despite preliminary second-quarter revenue of more than 90 million dollars roughly doubling year-over-year, as investors focused on geopolitical headwinds and operational challenges from an ERP system implementation. Intuitive Surgical slipped 9% even after beating earnings and revenue expectations, as the company maintained its full-year da Vinci procedure growth outlook of 13.5% to 15.5% and flagged tariff-related margin pressure.

StockStory analysts recommend avoiding STAAR Surgical despite its recent 16.2% gain to $27.81, citing three concerns. The company's revenue has declined at an annualized rate of 5.7% over the past two years, its free cash flow margin has dropped by 26.6 percentage points over five years to negative 18.9%, and its return on invested capital has significantly decreased, signaling limited profitable growth opportunities. With the stock trading at 37 times forward earnings, the analysts believe better opportunities exist elsewhere.

StockStory identifies IonQ as a cash-heavy stock to watch, citing its $2.00 billion net cash position, 172% annual revenue growth over two years, and projected 53.2% revenue growth for the next 12 months. In contrast, Columbia Sportswear and STAAR Surgical are flagged as stocks to sell. Columbia Sportswear holds a net cash position of $62.79 million but struggles with 5.8% annual revenue growth over five years and a weak free cash flow margin of 6.9%. STAAR Surgical has a net cash position of $94.57 million but faces a 5.7% annual revenue decline over two years and a 26.6 percentage point drop in free cash flow margin over five years.

StockStory identifies Richardson Electronics and STAAR Surgical as risky cash-burning stocks to sell, while naming Kratos as a high-risk, high-reward stock to watch. Richardson Electronics, trading at $18.10 per share with a forward P/E of 47.8x, posted a trailing 12-month free cash flow margin of negative 2.6% and annual revenue growth of just 1.5% over the last two years. STAAR Surgical, at $29.12 per share and 38.4x forward P/E, saw its free cash flow margin shrink by 26.6 percentage points over five years to negative 18.9%, alongside annual sales declines of 5.7%. In contrast, Kratos, priced at $54.01 per share with a 71.3x forward P/E, achieved average organic revenue growth of 14.6% over two years and is projected to grow revenue by 29.9% in the next 12 months, with earnings per share rising 15.8% annually.